Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Aimmune's IPO nets $149mm

Executive Summary

Aimmune Therapeutics Inc. (food allergy desensitization therapies) netted $149mm through its initial public offering of 10mm shares at $16. (The company had hoped to sell 8.3mm shares between $14-16.) Existing investors agreed to purchase 1.56mm of the IPO shares.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register